

# ISLHD HAEMATOLOGY CLINICAL TRIALS

## *Illawarra Cancer Care Centre*

### June 2024

### **ISLHD CANCER CLINICAL TRIALS UNIT**

**Illawarra Cancer Care Centre  
Wollongong Hospital  
Loftus Street  
Wollongong NSW 2500**

**Ph: 02 4253 4384**

**Fax: 02 4222 5085**

**Email: ISLHD-  
CancerClinicalTrials@health.  
nsw.gov.au**

**Clinical Trials available  
through the Illawarra  
Shoalhaven Local Health  
District can be found on  
the ClinTrial Refer App.  
Scan the QR code below  
to download ClinTrial  
Refer.**



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Multiple Myeloma
- Acute myeloid Leukaemia

### **REFERRAL OR CONSULTATION**

To discuss your patient with an ISLHD Haematology Trials Clinician, please phone Haematology on 02 4253 4009

# ISLHD Haematology Clinical Trials

## **\*\*CURRENTLY OPEN FOR RECRUITMENT\*\***

Scan the QR Code for more information including eligibility criteria

### Multiple Myeloma

**ACT16482:** Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM).

Dr Parmar  
Felicity Carroll-Cross/  
Cassandra Jory



**CA057-001:** A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM). **\*\*recruitment paused\*\***

Dr Parmar  
Kiara Porter/  
Tegan Cutter  
**\*Satellite site**



**MAJESTEC-7:** A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy.

Dr Parmar  
Carla Brown/  
Tegan Cutter



**MonumentAL-2:** A multi-arm phase 1b study of talquetamab with other anticancer therapies in participants with multiple myeloma.

Dr Parmar  
Tegan Cutter/  
Kiara Porter



**MonumentAL-6:** A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide.

Dr Parmar  
Tegan Cutter/  
Carla Brown



**TCD17710:** First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA).

Dr Parmar  
Felicity Carroll-Cross/  
Cassandra Jory



**LTS17704:** International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study. **\*\*Parental study TCD15484\*\***

Dr Parmar  
Tiffany Koutsouradis/  
Amelia Feneck



# ISLHD Haematology Clinical Trials

## **\*\*CURRENTLY OPEN FOR RECRUITMENT\*\***

### **Acute Leukaemia**

**AML M2/D2:** The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave  
Carla Brown



***For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email [ISLHD-HaematologyTrials@health.nsw.gov.au](mailto:ISLHD-HaematologyTrials@health.nsw.gov.au)***

<b><i>Trial Coordinator</i></b>	<b><i>Availability</i></b>	<b><i>Contact details</i></b>
Danielle Di Pietro (team leader)	Mon-Fri	02 4255 1415
Tameika Tubaro (CNS2)	Mon-Thurs	02 4222 5230
Felicity Carroll-Cross	Mon-Fri	02 4253 4039
Tegan Cutter	Mon-Fri	02 4253 4173
Kiara Porter	Mon-Fri	02 4222 5276
Carla Brown	Mon-Wed	02 4253 4082
Cassandra Jory	Wed-Fri	02 4222 5553
Tiffany Koutsouradis	Wed-Fri	02 4253 4933
Jillian Dubose	Tues-Fri	02 4255 1495
Amelia Feneck	Mon-Wed	02 4253 4933